Pharmacotherapy in autism spectrum disorders, including promising older drugs warranting trials
World Journal of Psychiatry · 19.06.2023 · 13 (6) · 262-277
DOI: 10.5498/wjp.v13.i6.262 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift World Journal of Psychiatry, online erschienen am 19.06.2023. Verfasst von Jessica Hellings. Beteiligte Einrichtung: Department of Psychiatry, University of Missouri-Kansas City, Lee's Summit, MO 64063, United States. jessica.hellings@uhkc.org. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Available pharmacotherapies for autism spectrum disorders (ASD) are reviewed based on clinical and research experience, highlighting some older drugs with emerging evidence. Several medications show efficacy in ASD, though controlled studies in ASD are largely lacking. Only risperidone and aripiprazole have Federal Drug Administration approval in the United States. Methylphenidate (MPH) studies showed lower efficacy and tolerability for attention deficit hyperactivity disorder (ADHD) than in the typically developing (TD) population; atomoxetine demonstrated lower efficacy but comparable tolerability to TD outcomes. Guanfacine improved hyperactivity in ASD comparably to TD. Dex-troamphetamine promises greater efficacy than MPH in ASD. ADHD medications reduce impulsive aggression in youth, and may also be key for this in adults. Controlled trials of the selective serotonin reuptake inhibitors citalopram and fluoxetine demonstrated poor tolerability and lack of efficacy for repetitive behaviors. Trials of antiseizure medications in ASD remain inconclusive, however clinical trials may be warranted in severely disabled individuals showing bizarre behaviors. No identified drugs treat ASD core symptoms; oxytocin lacked efficacy. Amitriptyline and loxapine however, show promise. Loxapine at 5-10 mg daily resembled an atypical antipsychotic in positron emission tomography studies, but may be weight-sparing. Amitriptyline at approximately 1 mg/ kg/day used cautiously, shows efficacy for sleep, anxiety, impulsivity and ADHD, repetitive behaviors, and enuresis. Both drugs have promising neurotrophic properties.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, University of Missouri-Kansas City, Lee's Summit, MO 64063, United States. jessica.hellings@uhkc.org.
Zitieren
APA
Hellings, J. (2023). Pharmacotherapy in autism spectrum disorders, including promising older drugs warranting trials. World Journal of Psychiatry, 13(6), 262-277. https://doi.org/10.5498/wjp.v13.i6.262
Vancouver
Hellings J. Pharmacotherapy in autism spectrum disorders, including promising older drugs warranting trials. World Journal of Psychiatry. 2023;13(6):262-277. doi:10.5498/wjp.v13.i6.262
BibTeX
@article{Hellings2023,
author = {Hellings, Jessica},
title = {Pharmacotherapy in autism spectrum disorders, including promising older drugs warranting trials},
journal = {World Journal of Psychiatry},
year = {2023},
volume = {13},
number = {6},
pages = {262--277},
doi = {10.5498/wjp.v13.i6.262}
}
EUVIMED